Preservation of lymphopoietic potential and virus suppressive capacity by CD8+ T cells in HIV-2-infected controllers

Journal of Immunology

Volumn 197, Issue 7, 2016, Pages 2787-2795

  Angin, Mathieu ^a   Wong, Glenn ^b,c   Papagno, Laura ^b   Versmisse, Pierre ^a   David, Annie ^a   Bayard, Charles ^b   De Muylder, Bénédicte Charmeteau ^d   Besseghir, Amel ^e   Thiébaut, Rodolphe ^e   Boufassa, Faroudy ^f   Pancino, Gianfranco ^a   Sauce, Delphine ^b   Lambotte, Olivier ^g,h,i   Brun Vézinet, Françoise ^j   Matheron, Sophie ^j,k   Rowland Jones, Sarah L ^c   Cheynier, Rémi ^d   Sáez Cirión, Asier ^a   Appay, Victor ^b  

^a INSTITUT PASTEUR   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d INSTITUT COCHIN   (France)

^e INSERM U657   (France)

^f CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^g INSERM U1184   (France)

^h BICÊTRE HOSPITAL   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

^j BICHAT HOSPITAL   (France)

^k UNIVERSITÉ PARIS DIDEROT   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD31 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAG PROTEIN; GAMMA INTERFERON; HLA B 2705 ANTIGEN; HLA B ANTIGEN; INTERLEUKIN 7 RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROTEIN P27; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL RENEWAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; INFECTION CONTROL; LYMPHOCYTE DIFFERENTIATION; LYMPHOPOIESIS; MALE; PREMATURE AGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMUS FUNCTION; VIRUS LOAD; VIRUS REPLICATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 2; IMMUNOLOGY; MIDDLE AGED; VIROLOGY;

ADULT; AGED; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-2; HUMANS; LYMPHOPOIESIS; MALE; MIDDLE AGED;

EID: 84989875015     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600693     Document Type: Article

References (66)

1. Gottlieb, G. S., P. S. Sow, S. E. Hawes, I. Ndoye, M. Redman, A. M. Coll-Seck, M. A. Faye-Niang, A. Diop, J. M. Kuypers, C. W. Critchlow, et al. 2002. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1-And HIV-2-infected individuals from Senegal, West Africa. J. Infect. Dis. 185: 905-914.
2. Michel, P., A. T. Balde, C. Roussilhon, G. Aribot, J. L. Sarthou, and M. L. Gougeon. 2000. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution. J. Infect. Dis. 181: 64-75.
3. Drylewicz, J., S. Matheron, E. Lazaro, F. Damond, F. Bonnet, F. Simon, F. Dabis, F. Brun-Vezinet, G. Chêne, and R. Thiébaut. 2008. Comparison of viroimmunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 22: 457-468.
4. Hodges-Mameletzis, I., G. J. De Bree, and S. L. Rowland-Jones. 2011. An underestimated lentivirus model: What can HIV-2 research contribute to the development of an effective HIV-1 vaccine? Expert Rev. Anti Infect. Ther. 9: 195-206.
5. Thiébaut, R., S. Matheron, A. Taieb, F. Brun-Vezinet, G. Chêne, and B. Autran, immunology Group of the ANRS CO5 HIV-2 Cohort. 2011. Long-Term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort. AIDS 25: 865-867.
6. Grabar, S., H. Selinger-Leneman, S. Abgrall, G. Pialoux, L. Weiss, and D. Costagliola. 2009. Prevalence and comparative characteristics of long-Term nonprogressors and HIV controller patients in the French hospital database on HIV. AIDS 23: 1163-1169.
7. Migueles, S. A., and M. Connors. 2015. Success and failure of the cellular immune response against HIV-1. Nat. Immunol. 16: 563-570.
8. Douek, D. C., R. D. McFarland, P. H. Keiser, E. A. Gage, J. M. Massey, B. F. Haynes, M. A. Polis, A. T. Haase, M. B. Feinberg, J. L. Sullivan, et al. 1998. Changes in thymic function with age and during the treatment of HIV infection. Nature 396: 690-695.
9. Sauce, D., M. Larsen, S. Fastenackels, M. Pauchard, H. Ait-Mohand, L. Schneider, A. Guihot, F. Boufassa, J. Zaunders, M. Iguertsira, et al. 2011. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 117: 5142-5151.
10. Dion, M. L., R. Bordi, J. Zeidan, R. Asaad, M. R. Boulassel, J. P. Routy, M. M. Lederman, R. P. Sekaly, and R. Cheynier. 2007. Slow disease progression and robust therapy-mediated CD4+ T-cell recovery are associated with efficient thymopoiesis during HIV-1 infection. Blood 109: 2912-2920.
11. Carrington, M., and S. J. O'Brien. 2003. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54: 535-551.
12. Sáez-Cirión, A., and G. Pancino. 2013. HIV controllers: A genetically determined or inducible phenotype? Immunol. Rev. 254: 281-294.
13. Sáez-Cirión, A., G. Pancino, M. Sinet, A. Venet, and O. Lambotte, ANRS EP36 HIV Controllers Study Group. 2007. HIV controllers: how do they tame the virus? Trends Immunol. 28: 532-540.
14. Lopes, A. R., A. Jaye, L. Dorrell, S. Sabally, A. Alabi, N. A. Jones, D. R. Flower, A. De Groot, P. Newton, R. M. Lascar, et al. 2003. Greater CD8+ TCR heterogeneity and functional flexibility in HIV-2 compared to HIV-1 infection. J. Immunol. 171: 307-316.
15. Leligdowicz, A., L. M. Yindom, C. Onyango, R. Sarge-Njie, A. Alabi, M. Cotten, T. Vincent, C. da Costa, P. Aaby, A. Jaye, et al. 2007. Robust Gagspecific T cell responses characterize viremia control in HIV-2 infection. J. Clin. Invest. 117: 3067-3074.
16. de Silva, T. I., Y. Peng, A. Leligdowicz, I. Zaidi, L. Li, H. Griffin, M. E. Blais, T. Vincent, M. Saraiva, L. M. Yindom, et al. 2013. Correlates of T-cell-mediated viral control and phenotype of CD8+ T cells in HIV-2, a naturally contained human retroviral infection. Blood 121: 4330-4339.
17. Dong, T., G. Stewart-Jones, N. Chen, P. Easterbrook, X. Xu, L. Papagno, V. Appay, M. Weekes, C. Conlon, C. Spina, et al. 2004. HIV-specific cytotoxic T cells from long-Term survivors select a unique T cell receptor. J. Exp. Med. 200: 1547-1557.
18. Almeida, J. R., D. A. Price, L. Papagno, Z. A. Arkoub, D. Sauce, E. Bornstein, T. E. Asher, A. Samri, A. Schnuriger, I. Theodorou, et al. 2007. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204: 2473-2485.
19. Sáez-Cirión, A., S. Y. Shin, P. Versmisse, F. Barré-Sinoussi, and G. Pancino. 2010. Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses. Nat. Protoc. 5: 1033-1041.
20. Albert, J., U. Bredberg, F. Chiodi, B. Böttiger, E. M. Fenyö, E. Norrby, and G. Biberfeld. 1987. A new human retrovirus isolate ofWest African origin (SBL- 6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB. AIDS Res. Hum. Retroviruses 3: 3-10.
21. O'Doherty, U., W. J. Swiggard, and M. H. Malim. 2000. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74: 10074-10080.
22. Dion, M. L., R. P. Sékaly, and R. Cheynier. 2007. Estimating thymic function through quantification of T-cell receptor excision circles. Methods Mol. Biol. 380: 197-213.
23. Appay, V., S. Fastenackels, C. Katlama, H. Ait-Mohand, L. Schneider, A. Guihot, M. Keller, B. Grubeck-Loebenstein, A. Simon, O. Lambotte, et al. 2011. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS 25: 1813-1822.
24. Lelièvre, J. D., G. Melica, E. Itti, C. Lacabaratz, S. Rozlan, A. Wiedemann, R. Cheynier, M. Meignan, R. Thiebaut, and Y. Levy. 2012. Initiation of c-ART in HIV-1 infected patients is associated with a decrease of the metabolic activity of the thymus evaluated using FDG-PET/computed tomography. J. Acquir. Immune Defic. Syndr. 61: 56-63.
25. Gautier, D., S. Beq, C. S. Cortesão, A. E. Sousa, and R. Cheynier. 2007. Efficient thymopoiesis contributes to the maintenance of peripheral CD4 T cells during chronic human immunodeficiency virus type 2 infection. J. Virol. 81: 12685- 12688.
26. Hegedus, A., S. Nyamweya, Y. Zhang, S. Govind, R. Aspinall, A. Mashanova, V. A. Jansen, H. Whittle, A. Jaye, K. L. Flanagan, and D. C. Macallan. 2014. Protection versus pathology in aviremic and high viral load HIV-2 infection-The pivotal role of immune activation and T-cell kinetics. J. Infect. Dis. 210: 752- 761.
27. Nunes-Cabaço, H., P. Matoso, R. B. Foxall, R. Tendeiro, A. R. Pires, T. Carvalho, A. I. Pinheiro, R. S. Soares, and A. E. Sousa. 2015. Thymic HIV-2 infection uncovers posttranscriptional control of viral replication in human thymocytes. J. Virol. 89: 2201-2208.
28. Junge, S., B. Kloeckener-Gruissem, R. Zufferey, A. Keisker, B. Salgo, J. C. Fauchere, F. Scherer, T. Shalaby, M. Grotzer, U. Siler, et al. 2007. Correlation between recent thymic emigrants and CD31+ (PECAM-1)CD4+ T cells in normal individuals during aging and in lymphopenic children. Eur. J. Immunol. 37: 3270-3280.
29. Briceno, O., A. Lissina, K. Wanke, G. Afonso, A. von Braun, K. Ragon, T. Miquel, E. Gostick, L. Papagno, K. Stiasny, et al. 2015. Reduced naïve CD8 T-cell priming efficacy in elderly adults. Aging Cell 15: 14-21.
30. Cicin-Sain, L., S. Smyk-Pearson, N. Currier, L. Byrd, C. Koudelka, T. Robinson, G. Swarbrick, S. Tackitt, A. Legasse, M. Fischer, et al. 2010. Loss of naive T cells and repertoire constriction predict poor response to vaccination in old primates. [Published erratum appears in 2010 J. Immunol. 185: 4509.] J. Immunol. 184: 6739-6745.
31. Duvall, M. G., M. L. Precopio, D. A. Ambrozak, A. Jaye, A. J. McMichael, H. C. Whittle, M. Roederer, S. L. Rowland-Jones, and R. A. Koup. 2008. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur. J. Immunol. 38: 350-363.
32. Goulder, P. J., R. E. Phillips, R. A. Colbert, S. McAdam, G. Ogg, M. A. Nowak, P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, et al. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3: 212-217.
33. Lécuroux, C., I. Girault, A. Urrutia, J. M. Doisne, C. Deveau, C. Goujard, L. Meyer, M. Sinet, and A. Venet. 2009. Identification of a particular HIV-specific CD8+ T-cell subset with a CD27+CD45RO-/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection. Blood 113: 3209-3217.
34. Leligdowicz, A., C. Onyango, L. M. Yindom, Y. Peng, M. Cotten, A. Jaye, A. McMichael, H. Whittle, T. Dong, and S. Rowland-Jones. 2010. Highly avid, oligoclonal, early-differentiated antigen-specific CD8+ T cells in chronic HIV-2 infection. Eur. J. Immunol. 40: 1963-1972.
35. Appay, V., P. R. Dunbar, M. Callan, P. Klenerman, G. M. Gillespie, L. Papagno, G. S. Ogg, A. King, F. Lechner, C. A. Spina, et al. 2002. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8: 379-385.
36. Appay, V., R. A. van Lier, F. Sallusto, and M. Roederer. 2008. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 73: 975-983.
37. Intlekofer, A. M., N. Takemoto, E. J. Wherry, S. A. Longworth, J. T. Northrup, V. R. Palanivel, A. C. Mullen, C. R. Gasink, S. M. Kaech, J. D. Miller, et al. 2005. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6: 1236-1244.
38. Sáez-Cirión, A., C. Lacabaratz, O. Lambotte, P. Versmisse, A. Urrutia, F. Boufassa, F. Barré-Sinoussi, J. F. Delfraissy, M. Sinet, G. Pancino, and A. Venet, Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group. 2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. USA 104: 6776-6781.
39. Sáez-Cirión, A., M. Sinet, S. Y. Shin, A. Urrutia, P. Versmisse, C. Lacabaratz, F. Boufassa, V. Avettand-Fènoël, C. Rouzioux, J. F. Delfraissy, et al. 2009. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: Association with Gag-specific CD8 T cell responses. J. Immunol. 182: 7828- 7837.
40. Lécuroux, C., I. Girault, A. Chéret, P. Versmisse, G. Nembot, L. Meyer, C. Rouzioux, G. Pancino, A. Venet, and A. Sáez-Cirión, ANRS 147 OPTIPRIM clinical trial. 2013. CD8 T-cells from most HIV-infected patients lack ex vivo HIV-suppressive capacity during acute and early infection. PLoS One 8: e59767.
41. Sáez-Cirión, A., C. Bacchus, L. Hocqueloux, V. Avettand-Fenoel, I. Girault, C. Lecuroux, V. Potard, P. Versmisse, A. Melard, T. Prazuck, et al. 2013. Posttreatment HIV-1 controllers with a long-Term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9: e1003211.
42. Tansiri, Y., S. L. Rowland-Jones, J. Ananworanich, and P. Hansasuta. 2015. Clinical outcome of HIV viraemic controllers and noncontrollers with normal CD4 counts is exclusively determined by antigen-specific CD8+ T-cell-mediated HIV suppression. PLoS One 10: e0118871.
43. Migueles, S. A., K. A. Weeks, E. Nou, A. M. Berkley, J. E. Rood, C. M. Osborne, C. W. Hallahan, N. A. Cogliano-Shutta, J. A. Metcalf, M. McLaughlin, et al. 2009. Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J. Virol. 83: 11876-11889.
44. Yang, H., H. Wu, G. Hancock, G. Clutton, N. Sande, X. Xu, H. Yan, X. Huang, B. Angus, K. Kuldanek, et al. 2012. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J. Infect. Dis. 206: 552-561.
45. Spentzou, A., P. Bergin, D. Gill, H. Cheeseman, A. Ashraf, H. Kaltsidis, M. Cashin-Cox, I. Anjarwalla, A. Steel, C. Higgs, et al. 2010. Viral inhibition assay: A CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J. Infect. Dis. 201: 720-729.
46. Damond, F., D. Descamps, I. Farfara, J. N. Telles, S. Puyeo, P. Campa, A. Leprêtre, S. Matheron, F. Brun-Vezinet, and F. Simon. 2001. Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-Time PCR. J. Clin. Microbiol. 39: 4264-4268.
47. Matheron, S., S. Pueyo, F. Damond, F. Simon, A. Leprêtre, P. Campa, R. Salamon, G. Chêne, and F. Brun-Vezinet, French HIV-2 Cohort Study Group. 2003. Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort. AIDS 17: 2593-2601.
48. Foxall, R. B., C. S. Cortesão, A. S. Albuquerque, R. S. Soares, R. M. Victorino, and A. E. Sousa. 2008. Gag-specific CD4+ T-cell frequency is inversely correlated with proviral load and directly correlated with immune activation in infection with human immunodeficiency virus type 2 (HIV-2) but not HIV-1. J. Virol. 82: 9795-9799.
49. Noel, N., R. Peña, A. David, V. Avettand-Fenoel, I. Erkizia, E. Jimenez, C. Lecuroux, C. Rouzioux, F. Boufassa, G. Pancino, et al. 2016. Long-Term spontaneous control of HIV-1 is related to low frequency of infected cells and inefficient viral reactivation. J. Virol. 90: 6148-6158.
50. Pereyra, F., M. M. Addo, D. E. Kaufmann, Y. Liu, T. Miura, A. Rathod, B. Baker, A. Trocha, R. Rosenberg, E. Mackey, et al. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197: 563-571.
51. Emu, B., E. Sinclair, H. Hatano, A. Ferre, B. Shacklett, J. N. Martin, J. M. McCune, and S. G. Deeks. 2008. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-Term virus control. J. Virol. 82: 5398-5407.
52. Ndhlovu, Z. M., J. Proudfoot, K. Cesa, D. M. Alvino, A. McMullen, S. Vine, E. Stampouloglou, A. Piechocka-Trocha, B. D.Walker, and F. Pereyra. 2012. Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses. J. Virol. 86: 6959-6969.
53. Ndhlovu, Z. M., E. Stampouloglou, K. Cesa, O. Mavrothalassitis, D. M. Alvino, J. Z. Li, S. Wilton, D. Karel, A. Piechocka-Trocha, H. Chen, et al. 2015. The breadth of expandable memory CD8+ T cells inversely correlates with residual viral loads in HIV elite controllers. J. Virol. 89: 10735-10747.
54. Ferre, A. L., P. W. Hunt, J. W. Critchfield, D. H. Young, M. M. Morris, J. C. Garcia, R. B. Pollard, H. F. Yee Jr., J. N. Martin, S. G. Deeks, and B. L. Shacklett. 2009. Mucosal immune responses to HIV-1 in elite controllers: A potential correlate of immune control. Blood 113: 3978-3989.
55. Diouf, K., A. D. Sarr, G. Eisen, S. Popper, S. Mboup, and P. Kanki. 2002. Associations between MHC class I and susceptibility to HIV-2 disease progression. J. Hum. Virol. 5: 1-7.
56. Yindom, L. M., A. Leligdowicz, M. P. Martin, X. Gao, Y.Qi, S. M. Zaman, M. S. van der Loeff, C. van Tienen, A. Jaye, A. Aveika, et al. 2010. Influence of HLA class I and HLA-KIR compound genotypes on HIV-2 infection and markers of disease progression in a Manjako community in West Africa. J. Virol. 84: 8202-8208.
57. Carrington, M., G. W. Nelson, M. P. Martin, T. Kissner, D. Vlahov, J. J. Goedert, R. Kaslow, S. Buchbinder, K. Hoots, and S. J. O'Brien. 1999. HLA and HIV-1: heterozygote advantage and B∗35-Cw∗04 disadvantage. Science 283: 1748- 1752.
58. Tang, J., C. Costello, I. P. Keet, C. Rivers, S. Leblanc, E. Karita, S. Allen, and R. A. Kaslow. 1999. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 15: 317-324.
59. Liu, Y., J. McNevin, J. Cao, H. Zhao, I. Genowati, K. Wong, S. McLaughlin, M. D. McSweyn, K. Diem, C. E. Stevens, et al. 2006. Selection on the human immunodeficiency virus type 1 proteome following primary infection. J. Virol. 80: 9519-9529.
60. Ylinen, L. M., Z. Keckesova, S. J. Wilson, S. Ranasinghe, and G. J. Towers. 2005. Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. J. Virol. 79: 11580-11587.
61. Jia, B., R. Serra-Moreno, W. Neidermyer, A. Rahmberg, J. Mackey, I. B. Fofana, W. E. Johnson, S. Westmoreland, and D. T. Evans. 2009. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 5: e1000429.
62. Le Tortorec, A., and S. J. Neil. 2009. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83: 11966-11978.
63. Bertine, M., C. Charpentier, B. Visseaux, A. Storto, G. Collin, L. Larrouy, F. Damond, S. Matheron, F. Brun-Vézinet, and D. Descamps, ANRS CO5 HIV-2 Cohort. 2015. High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients. AIDS 29: 779-784.
64. Manel, N., B. Hogstad, Y. Wang, D. E. Levy, D. Unutmaz, and D. R. Littman. 2010. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 467: 214-217.
65. Duvall, M. G., K. Loré, H. Blaak, D. A. Ambrozak, W. C. Adams, K. Santos, C. Geldmacher, J. R. Mascola, A. J. McMichael, A. Jaye, et al. 2007. Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection. J. Virol. 81: 13486-13498.
66. Chauveau, L., I. Puigdomenech, D. Ayinde, F. Roesch, F. Porrot, D. Bruni, B. Visseaux, D. Descamps, and O. Schwartz. 2015. HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells. Retrovirology 12: 2.